You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 11,517,609


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,517,609
Title:Glycopeptide compositions
Abstract:Solutions comprising a glycopeptide antibiotic, for example Vancomycin, and an amino acid or amino acid derivative such as N-acetyl-Glycine or N-acetyl-D-Alanine are provided. These solutions are stable or stabilized for long-term periods at conditions of normal use and storage, and can be formulated as pharmaceutical solutions for use in subjects. Methods of manufacturing and using these solutions are also provided, as are methods of stabilizing a glycopeptide antibiotic, for example Vancomycin, using amino acids or amino acid derivatives such as N-acetyl-Glycine or N-acetyl-D-Alanine.
Inventor(s):Jasprica Ivona, Keser Sabina, Pindric Katarina
Assignee:Xellia Pharmaceuticals ApS
Application Number:US17860642
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Understanding the Scope and Claims of a US Patent: A Detailed Analysis

Introduction

When navigating the complex landscape of US patents, understanding the scope and claims of a patent is crucial for inventors, patent applicants, and legal professionals. This article will delve into the key aspects of patent scope, claim drafting, and the broader patent landscape, using the example of US Patent 11,517,609 to illustrate these concepts.

What is a Patent Claim?

A patent claim is a statement that defines the scope of protection granted to an inventor for their invention. It is the most critical part of a patent application, as it delineates what the inventor considers to be their invention and what they seek to protect[5].

Importance of Claim Scope

The scope of a patent claim is vital because it determines the boundaries of the inventor's exclusive rights. A common misconception is that broader claims are always better, but this is not necessarily true. Broader claims can be more challenging to get allowed and may increase the risk of invalidation due to prior art or failure to meet statutory requirements[5].

Metrics for Measuring Patent Scope

Researchers have proposed simple metrics to measure patent scope, such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes. Narrower claims are often associated with a higher probability of grant and a shorter examination process[3].

Drafting Claims: Best Practices

When drafting claims, it is essential to ensure they are anchored to the embodiments described in the specification. Claims that are overly broad and not supported by the specification can be invalidated on grounds such as the abstract idea exception or failure to meet the written description requirement[5].

The Role of Inventorship

Correctly determining who should be listed as an inventor is crucial for the validity of a patent. US patent law requires that only the "true and only" inventors be listed. Joint inventorship occurs when multiple individuals contribute significantly to the subject matter of the patent claims. Errors in inventorship, especially those involving deceptive intent, can render a patent unenforceable[2].

Patent Quality and Examination Process

The quality of a patent is closely tied to the examination process. The USPTO has implemented various initiatives to improve patent quality, including defining what constitutes a quality patent and reassessing the time allotted for examination. A quality patent is one that is correctly issued in compliance with all statutory requirements and relevant case law at the time of issuance[1].

Time Allotted for Examination

The time examiners have to perform a thorough patent examination is a critical factor in patent quality. The USPTO has analyzed and adjusted the time available for certain technology areas, recognizing that more time may be needed for thorough searches in complex fields. This adjustment aims to ensure that examiners have sufficient time to evaluate patent applications accurately[1].

Claim Clarity Tools

While the USPTO has considered requiring applicants to use claim clarity tools such as glossaries of terms or claim charts, stakeholders have not supported such a requirement. Instead, the USPTO focuses on other measures to enhance claim clarity and overall patent quality[1].

Obviousness and Prior Art

A patent claim is invalid if the differences between the claimed invention and the prior art are such that the claimed invention would have been obvious to a person having ordinary skill in the art. The Federal Circuit has emphasized that obviousness is a question of law based on underlying findings of fact, including the scope and content of the prior art and the level of ordinary skill in the pertinent art[4].

Case Studies: Risks of Overly Broad Claims

Recent court decisions, such as Yu v. Apple Inc. and Minerva Surgical, Inc. v. Hologic, Inc., highlight the risks of overly broad claims. These cases illustrate how claims that are not adequately supported by the specification can be invalidated under the abstract idea exception or other statutory requirements[5].

Example: US Patent 11,517,609

While specific details of US Patent 11,517,609 are not provided here, the principles outlined above apply universally. Here’s how these concepts might be relevant:

  • Claim Scope: The claims in this patent should be carefully drafted to ensure they are neither too broad nor too narrow. They must be supported by the detailed description in the specification.
  • Inventorship: The inventors listed must have contributed significantly to the subject matter of the patent claims.
  • Examination Process: The patent would have undergone a thorough examination process, with examiners having sufficient time to evaluate the application.
  • Obviousness: The claims must demonstrate non-obviousness over the prior art, ensuring that the invention is novel and non-obvious to a person having ordinary skill in the art.

Key Takeaways

  • Claim Scope is Critical: Ensure claims are neither too broad nor too narrow and are well-supported by the specification.
  • Inventorship Accuracy: Correctly identify and list all true and only inventors to avoid invalidation.
  • Patent Quality Initiatives: The USPTO's initiatives to improve patent quality, such as defining patent quality and adjusting examination time, are crucial for maintaining high standards.
  • Avoid Overly Broad Claims: Such claims can lead to invalidation and increased litigation costs.
  • Thorough Examination: Adequate time for examiners to evaluate applications is essential for ensuring patent quality.

FAQs

Q: What is the importance of claim scope in a US patent application? A: The claim scope defines the boundaries of the inventor's exclusive rights and must be carefully drafted to avoid invalidation and ensure enforceability.

Q: How does the USPTO measure patent quality? A: The USPTO measures patent quality through various metrics, including compliance with statutory requirements and relevant case law, and uses correctness measures and quantifiable compliance targets.

Q: What are the risks of overly broad claims in a patent application? A: Overly broad claims can be easier to invalidate due to prior art or failure to meet statutory requirements, such as the abstract idea exception or the written description requirement.

Q: Why is accurate inventorship important in a patent application? A: Accurate inventorship is crucial to ensure the patent's validity; errors, especially those involving deceptive intent, can render the patent unenforceable.

Q: How does the USPTO ensure sufficient time for patent examination? A: The USPTO has analyzed and adjusted the time available for examiners to ensure they have sufficient time to evaluate complex patent applications thoroughly.

Sources

  1. GAO Report: Intellectual Property: Patent Office Should Define Quality, Reassess Time Allotted for Examination, and Analyze Incentives.
  2. Oregon State University: Determining Inventorship for US Patent Applications.
  3. SSRN Paper: Patent Claims and Patent Scope.
  4. Federal Circuit Court Decision: Fox Factory v. SRAM, LLC.
  5. Rimon Law: The Importance of Getting the Claim Scope Right in a US Patent Application.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 11,517,609

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-002 Feb 15, 2019 RX Yes Yes 11,517,609 ⤷  Subscribe METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-006 May 13, 2020 RX Yes Yes 11,517,609 ⤷  Subscribe METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-003 Feb 15, 2019 RX Yes Yes 11,517,609 ⤷  Subscribe METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-007 May 13, 2020 RX Yes Yes 11,517,609 ⤷  Subscribe METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-004 Feb 15, 2019 RX Yes Yes 11,517,609 ⤷  Subscribe METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-001 Feb 15, 2019 RX Yes Yes 11,517,609 ⤷  Subscribe METHOD OF TREATING BACTERIAL INFECTIONS ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,517,609

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015341763 ⤷  Subscribe
Brazil 112017009405 ⤷  Subscribe
Canada 2964524 ⤷  Subscribe
Chile 2017001139 ⤷  Subscribe
China 107073072 ⤷  Subscribe
Colombia 2017005391 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.